Cassava Sciences Inc

SAVA

NASDAQ. Currency in USD

38.10 -0.60 ( -1.55% )

Real time prices: December 19

Market Cap.

1.59B

Beta (5Y monthly)

0.03 Price/Earnings

-

EPS (TTM)

-1.78

Forward Dividend

0.00 (0.00%)

Ex-Dividend Date

Dec 17, 2012

Volume

713,619

1y Target Est.

69.75 Day's Range

37.06

38.76

52 Week's Range

13.84

62.49

Historical Summary

Performance

1 Month

14.31%

YTD

-12.81%

1Y

-11.95%

2Y

373.88%

117.80% ann.

3Y

1,905.26%

171.62% ann.

EPS growth

1Y

-223.64%

2Y

-641.67%

-132.96% ann.

3Y

-709.09%

-82.63% ann.

5Y

5.31%

1.04% ann.

10Y

-535.94%

-15.87% ann.

20Y

54.59%

2.20% ann.

Share Buybacks

3 Months

0.12%

6 Months

-0.22%

1Y

-0.23%

2Y

-60.38%

3Y

-133.36%

5Y

-512.57%

10Y

-528.57%

20Y

-934.72%

About Cassava Sciences Inc

Sector

Healthcare

Industry

Biotechnology

Website

https://www.cassavasciences.com

Exchange

NASDAQ (XNAS)

Shares Outstanding

40.02M

Employees

24 Address

7801 North Capital of Texas Highway, Austin, TX, United States, 78731

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Latest news

Is Anavex Life Sciences a Buy?

It still needs to prove that its lead program is as effective as it claims...
By The Motley Fool - 7 weeks ago

AXSM -3.30%

SAVA -1.55%

AVXL -1.50%

Tesla, Apple, GameStop, Prometheus Biosciences, Cassava Sciences: Why These 5 Stocks Are Drawing Investors' Attention Today

U.S. markets continued their weak trend on Wednesday, with next week’s Federal Open Market Committee...
By Benzinga - 8 weeks ago